Press Releases June 17, 2026 Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026 June 5, 2026 Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 4, 2026 Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026 Stock Information Minimum 15 minutes delayed. Source: LSEG
June 17, 2026 Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026